TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32004636
Drug: OLZ/SAM (10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ/SAM (10/10 mg on days 2-4, 20/20 mg on days 5-8, 30/30 mg on days 9-13)
Study: 32004636
Drug: OLZ/SAM (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ/SAM (all doses)
Study: 32691466
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (including H2 receptor antagonists, alginates, baclofen, antidepressants)
Study: 32353962
Drug: MgCl2 (ReMag®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgCl2 (ReMag®, 300 mg)
Study: 35067237
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment for weight loss
Study: 32168423
Drug: sST2-guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sST2-guided treatment (known sST2 level)
Study: 32168423
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (unknown sST2 level)
Study: 32406009
Drug: TJ-28 (7500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-28 (7500 mg/day)
Study: 32406009
Drug: Pyridoxine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (60 mg/day)
Study: 32763872
Drug: Wrist-worn Fitbit
Normalized name: histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wrist-worn Fitbit Flex and app, weekly challenges, digital behavior change resources, email or text message alerts
Study: 32763872
Drug: Weekly challenges
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly challenges
Study: 32744208
Drug: Monthly projections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly projections
Study: 36303476
Drug: Antibiotic-impregnated catheter
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated catheter
Study: 32470703
Drug: Melatonin implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin implant @ 18mg/50 kg B.Wt
Study: 34049869
Drug: Interactive web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive web-based learning module on medication safety
Study: 34049869
Drug: Five articles
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five articles to read about medication safety (Control)
Study: 32333510
Drug: QR678 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QR678 therapy
Study: 35279105
Drug: Subcutaneous rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rhEPO (10,000 IU daily from 5 days preoperatively to 3 days postoperatively)
Study: 35279105
Drug: Subcutaneous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous normal saline (1 ml daily from 5 days preoperatively to 3 days preoperatively) followed by rhEPO (10,000 IU daily until 3 days postoperatively)
Study: 35279105
Drug: Subcutaneous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous normal saline (1 ml daily from 5 days preoperatively to 1 day preoperatively) followed by rhEPO (10,000 IU daily from the day of surgery to 3 days postoperatively)
Study: 33720651
Drug: Sinupret (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinupret (herbal medicine in oral drops)
Study: 33720651
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment supplemented with topical antibacterial drugs
Study: 35331534
Drug: Probiotic (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (8 × 10^9 CFU/day) plus 200 μg/day selenium
Study: 32616063
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg/day for three days, followed by 200 mg/day for 11 days
Study: 32616063
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets for three days, followed by one tablet for 11 days)
Study: 36383882
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg oral NAC
Study: 36383882
Drug: rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: rectal indomethacin 100 mg
Study: 36383882
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg oral NAC plus rectal indomethacin 100 mg
Study: 33742692
Drug: Nitrate-rich diet
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich diet (200 mg of nitrate daily from lettuce juice beverage)
Study: 32924550
Drug: Topical Costus
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Costus sp. oil
Study: 32924550
Drug: Topical paraffin
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paraffin (placebo)
Study: 38422473
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (specifics not provided)
Study: 35405335
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential enrichment design
Study: 34937223
Drug: Cold saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold saline solution (0.9% NaCl)
Study: 34937223
Drug: Topical ophthalmic
Normalized name: MIOTICS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic proparacaine
Study: 34273676
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg)
Study: 32143685
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab 2 mg/kg (N=241; week 0, week 4, every 8 weeks)
Study: 34258264
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptive (COC) pills (3 mg drospirenone and 0.03 mg ethinyl estradiol daily for 6 weeks)
Study: 32065946
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation (BA) plus an exercise prescription
Study: 32065946
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation (BA) plus a stretching prescription
Study: 33119135
Drug: Food insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Food insulin index algorithm
Study: 35959593
Drug: Placebo (white
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (white capsule)
Study: 35959593
Drug: Nocebo (yellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocebo (yellow capsule)
Study: 35959593
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no capsule)
Study: 32433165
Drug: Fixed low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose (FLD) of 259 MBq of I
Study: 32433165
Drug: Fixed high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed high dose (FHD) of 555 MBq of I
Study: 32433165
Drug: Calculated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated dose (CD) to deliver 5.55 MBq/g of I
Study: 35028314
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine orally
Study: 32970104
Drug: Plinabulin 20
Normalized name: Plinabulin
DrugBank: Plinabulin (DB05992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plinabulin 20 mg/m2 on day 1
Study: 32970104
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg on day 2
Study: 34718548
Drug: Allogeneic administration
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with standard treatment for frailty
Study: 34718548
Drug: Allogeneic administration
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic administration of umbilical cord-derived MSCs (UC-MSCs)
Study: 32394652
Drug: Kinematic-acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinematic-acupuncture therapy and rehabilitation training
Study: 35504312
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy using a novel approach that combines computational modeling and deep learning.
Study: 32451788
Drug: Treatment-as-usual waitlist
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual waitlist control
Study: 32239448
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training (weekly sessions for 8 weeks)
Study: 36040772
Drug: Psilocybin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin treatment (25 mg oral administration) with psychological support for 5-8 hours
Study: 36040772
Drug: Psilocybin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin treatment
Study: 36320214
Drug: Standardized licorice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized licorice syrup as an adjuvant treatment plus standard care (Syrup Group, N = 91)
Study: 32789561
Drug: Lifetime history
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifetime history of mental health treatment and problems accessing adequate healthcare
Study: 36028878
Drug: Rosemary cream
DrugBank: Rosemary (DB14272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosemary cream
Study: 32995944
Drug: Pridopidine 90
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 90 mg
Study: 34545545
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (gemcitabine and cisplatin) for 6 cycles
Study: 34021888
Drug: Serratus anterior
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus anterior block + general anesthesia + patient‐controlled intravenous analgesia (PCIA group)
Study: 32345788
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA therapy
Study: 32345788
Drug: CEE-alone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE-alone therapy
Study: 35360984
Drug: Cannula group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannula group (short peripheral intravenous cannula with straight-tip guide-wire)
Study: 33094728
Drug: Empagliflozin (EMPA)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin (EMPA) 25 mg/day for 24 weeks
Study: 32493872
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (30 minutes daily for 6 months)
Study: 32493872
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with 30 minutes of quiet rest (control)
Study: 35048627
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg tablets one time per day for 7 days
Study: 36282607
Drug: Ketone supplement
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone supplement (7 g of beta-hydroxybutyrate, total of 14 g/d)
Study: 35210264
Drug: Tocilizumab (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (162 mg per week)
Study: 33186516
Drug: SF2a‐TT15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF2a‐TT15 vaccine candidate (2 μg dose)
Study: 33186516
Drug: SF2a‐TT15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF2a‐TT15 vaccine candidate (10 μg dose)
Study: 33186516
Drug: SF2a‐TT15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF2a‐TT15 vaccine candidate (2 μg dose, adjuvanted with alum)
Study: 33186516
Drug: SF2a‐TT15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF2a‐TT15 vaccine candidate (adjuvanted and non-adjuvanted)
Study: 33186516
Drug: SF2a‐TT15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF2a‐TT15 vaccine candidate
Study: 34749699
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (SOT)
Study: 33210382
Drug: NUC-1031 625
Normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-1031 625 mg/m2 and cisplatin 25 mg/m2
Study: 33210382
Drug: NUC-1031 725
Normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-1031 725 mg/m2 and cisplatin 25 mg/m2
Study: 36342237
Drug: ANH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANH and Standard treatment
Study: 35970940
Drug: Lovastatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (60 mg/day for 3 days)
Study: 35922101
Drug: Tailored text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored text messaging (none vs twice weekly messages).
Study: 34481498
Drug: Empagliflozin and
Normalized name: Empagliflozin and Linagliptin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin and Linagliptin (E+L group)
Study: 34481498
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Insulin Glargine (M+I group)
Study: 39066638
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/day
Study: 37142730
Drug: Adjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gemcitabine treatment
Study: 86073140
Drug: Intravenous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous glucagon
Study: 35541985
Drug: Pranayama intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pranayama intervention (twice daily for 28 days)
Study: 35541985
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal daily routine, no pranayama)
Study: 34489271
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy plus scalp acupuncture
Study: 34489271
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy alone
Study: 32502040
Drug: Standard COPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard COPD drugs
Study: 35329869
Drug: Iloprost inhalation
Normalized name: Iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost inhalation
Study: 35329869
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline inhalation)
Study: 33870587
Drug: IAN collagen‐membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN collagen‐membrane wrapping and interposing bone graft to overlay 23 implants
Study: 33870587
Drug: Conventional IANL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IANL in direct contact with 20 implants
Study: 36108662
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks for up to 18 cycles
Study: 36108662
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously every 3 weeks for up to 18 cycles
Study: 37589219
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg
Study: 34077831
Drug: High-dose mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mycophenolate mofetil (≥ 2000 mg/day)
Study: 34077831
Drug: Low-dose mycophenolate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mycophenolate mofetil (< 1000 mg/day)
Study: 34077831
Drug: Moderate-dose mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose mycophenolate mofetil (1000 mg/day ≤ MMF dose < 2000 mg/day)
Study: 34871375
Drug: Best guideline-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best guideline-directed medical therapy
Study: 33446608
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (6 mg once daily for 4 days)
Study: 34921663
Drug: Dexmedetomidine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine combined with Butorphanol (1 mg)
Study: 33261645
Drug: Rice protein
Normalized name: rice protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice protein (24g daily)
Study: 33261645
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (24g daily)
Study: 35020685
Drug: Orofacial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial treatment (physical therapy and occlusal splints)
Study: 35020685
Drug: Orofacial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial treatment
Study: 35020685
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no other treatment)
Study: 34351414
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 16 weeks after 3 initial monthly doses (2q16 group)
Study: 34351414
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 8 weeks after 5 initial monthly doses with PRN dosing (2q8/PRN group)
Study: 34351414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sham injections)
Study: 34351414
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 16 weeks (2q16 group)
Study: 34351414
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 8 weeks with PRN dosing (2q8/PRN group)
Study: 32150297
Drug: Bortezomib maintenance
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib maintenance (1·3 mg/m2 intravenously once every 2 weeks, for 2 years)
Study: 38288936
Drug: Anifrolumab 300
Normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab 300 mg
Study: 32280042
Drug: 1-week, 4-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week, 4-site intradermal (ID) rabies vaccination without ERIG (Group 1)
Study: 32280042
Drug: 1-week, 4-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week, 4-site intradermal (ID) rabies vaccination with ERIG (Group 2)
Study: 35703367
Drug: Touch therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Touch therapy
Study: 612365097
Drug: ONO-9054 (0.003%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-9054 (0.003%, 30 mug/mL) once daily for 28 days
Study: 612365097
Drug: Xalatan (0.005%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalatan (0.005%, 50 mug/mL) once daily for 28 days
Study: 33711380
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intravitreal pegcetacoplan
Study: 34525247
Drug: Pre‐emptive 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive 800mg of intravenous ibuprofen plus 1000mg of intravenous paracetamol (Group IP)
Study: 34525247
Drug: Only 1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only 1000mg of intravenous paracetamol (Group P)
Study: 33242754
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg, days 1–4)
Study: 32558305
Drug: topical nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical nepafenac (1 mg/ml) 1 drop 3 times per day for 3 days before surgery
Study: 32558305
Drug: not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: not receiving topical nepafenac (control group)
Study: 35697571
Drug: Single booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single booster dose of 4CMenB in the infant + preschool group
Study: 35697571
Drug: Single booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single booster dose of 4CMenB in the infant group
Study: 35697571
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 4CMenB in naïve age-matched controls (adolescent 2 group)
Study: 32445881
Drug: Monotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy group (IFN-α2b inhalation for 10–14 days)
Study: 35483677
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 μg/kg
Study: 33541815
Drug: 2% Olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Olive Leaf Extract (OLE) cream
Study: 34967353
Drug: nano-modified Runji
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano-modified Runji ointment
Study: 35668682
Drug: Vehicle formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle formulation
Study: 36117205
Drug: Dietary Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Insulin Load (DIL) highest quartile
Study: 36117205
Drug: Dietary Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Insulin Load (DIL) highest quartile, adjusted for confounders
Study: 36117205
Drug: Dietary Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Insulin Load (DIL) highest quartile, further adjusted for BMI
Study: 36117205
Drug: Dietary Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Insulin Index (DII)
Study: 36117205
Drug: Dietary Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Insulin Load (DIL)
Study: 32563846
Drug: Goal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal of opioid abstinence at treatment entry